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Background: Transmitted drug resistance (TDR) is mainly restricted to individuals carrying B subtype, with low
prevalence among non-B subtypes when grouped together. Subtype F1 is the most frequent non-B variant
found in subjects living in Italy, allowing a specific assessment of TDR associated with this clade.
Methods: We analysed pol sequences of HIV-1-positive individuals carrying the F1 variant included in the Anti-
retroviral Resistance Cohort Analysis database in the 1998–2009 period. Mutations were analysed with the Sur-
veillance Drug Resistance Mutation and the International AIDS Society lists for naive and treated patients,
respectively.
Results: Among 343 HIV-1-infected patients carrying an F1 subtype, resistance was evaluated in a subset of
221 patients whose treatment status was known (169 drug naive and 52 drug experienced). The prevalence
of TDR was 15.4% (11.8% for nucleoside/nucleotide reverse transcriptase inhibitors, 6.5% for non-nucleoside
reverse transcriptase inhibitors and 7.1% for protease inhibitors). Among the 169 naive patients, 75.1%,
10.1% and 7.1% were Italians, South Americans and Romanians, respectively. Heterosexuals were prevalent
among Italians and Romanians, while men who have sex with men were predominant among South Amer-
icans. The overall frequency of TDR declined from 21.4% to 7.1% in the 1998–2009 period. Although no stat-
istical difference was detected, the frequency of TDR was higher in South Americans (23.5%) compared with
Italian and Romanian naive patients (15% and 8.3%, respectively).
Discussion: Our study shows a remarkable frequency of TDR in the F1 subtype-infected population. The high
prevalence of TDR detected in South American subjects is linked to the homosexual route of infection.
However, TDR was considerably high also in Italian subjects harbouring the F1 subtype, deserving careful
monitoring.
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Introduction
Transmitted drug resistance (TDR) is an important concern in HIV-1
treatment, representing the major factor that may compromise
the efficacy of the initial highly active antiretroviral therapy
(HAART) regimen.1 Therefore, international and national guide-
lines recommend the detection of baseline drug susceptibility to
guide an optimal treatment choice (http://www.aidsinfo.nih.
gov/ContentFiles/AdultandAdolescentGL.pdf). Although some
reports have shown a decreasing or stabilizing prevalence
of fTDR in recent years,2,3 more data are needed to confirm this
trend.
Studies performed in several European countries have shown
that TDR is mainly restricted to individuals carrying the B
subtype; however, the strength of this association may vary
according to the spread of non-B clades in different countries at
the time of survey.4 – 7 Despite the considerable waves of migration
from Africa, Central and South America, and South-East Asia, TDR
in patients with non-B subtypes was reported at low frequency in
Europe until recent years. This prevalence was shown to fluctuate
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from 6% in the 2001–03 period to 3.2% in 2006 in the UK,4 while
surveillance studies reported a prevalence of 11% in France.5 We
previously reported a TDR prevalence of 5% in individuals harbour-
ing a non-B clade virus from 1992 to 2005 in Italy,6 whilst another
Italian study, conducted in the period 1996–2006, showed a TDR
prevalence of 7%, which was significantly lower than that found in
B subtype-carrying patients (17%).7
European surveillance studies have so far considered TDR in
non-B clades grouped together. However, TDR analysis in specific
non-B clades may provide interesting data if related with epi-
demiological correlates, such as the country of origin and the
modality of infection.
Subtype F1 is the most frequent non-B variant (44.3%) found
in subjects living in Italy,8 thus allowing a specific assessment of
TDR associated with this clade. This subtype, both as a ‘pure’
strain or as part of recombinant forms, is circulating at high
prevalence in South America, Central Africa and Eastern
Europe. In South America it circulates at high frequency among
intravenous drug users (IDUs) and heterosexuals (HETs),9
whereas it has become highly prevalent in Romania (.70%)
among adults and institutionalized children.10
The aim of this study was to determine the prevalence of drug
resistance and TDR among F1 subtype HIV-1-infected patients,
whose genotype and clinical data have been recorded in a na-
tional database since 1998. Furthermore, we investigated the re-
lationship between drug resistance and the main demographic
variables, such as ethnicity, route of infection and gender
among naive patients.
Methods
We analysed HIV-1-positive individuals carrying the F1 variant, who had
been referred to 50 clinical centres in 13 Italian regions in the 1998–
2009 period. Patients received a genotypic resistance test at diagnosis
or prior to the start of therapy, or at treatment failure. Patients were
included in the Antiretroviral Resistance Cohort Analysis database and
provided informed consent to have their anonymized data stored on a
central server (www.hivarca.net). For each patient included in the ana-
lysis, the earliest available HIV-1 genotype was evaluated. Demographic
data (gender, risk category, country of origin, date of diagnosis and age)
were recorded in the database together with virological, immunological
and clinical information.
Subtyping was based on a partial HIV-1 pol sequence of 1000–1280
nucleotides long, depending on the sequencing protocol used at the con-
tributing laboratory.
Non-B sequences were aligned to the most recent reference dataset
from the Los Alamos National Laboratory web site (http://hiv.lanl.gov/)
using BioEdit 7.0.5 and ClustalX 1.83. The resulting alignment was analysed
with Phylip package version 3.67 (http://evolution.genetics.washington.
edu/phylip.html), building a neighbour-joining tree based on the Kimura
two-parameter substitution model. The reliability of the tree topology
was assessed through bootstrapping using 1000 replicate datasets.
Mutations related to drug resistance were analysed with the Surveil-
lance Drug Resistance Mutation11 and the International AIDS Society
lists12 for naive and treated patients. The distribution of study subjects
with regard to categorical parameters was compared using x2 or
Fisher’s exact tests. Standard non-parametric methods (Kruskal–Wallis
test) were used to compare the median age, HIV-1 RNA levels and CD4
counts. Categorical data were analysed using linear-by-linear associa-
tions for trends over time periods. For all analyses, an a error of 5%
was considered. Statistical calculations were performed using the statis-
tical software package SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results
We studied 343 HIV-1-infected patients enrolled in the 1998–
2009 period carrying the F1 subtype. Resistance was evaluated
in a subset of 221 patients whose treatment status was
known, of whom 169 were drug naive.
Among naive patients, 75.1% (n¼127), 10.1% (n¼17) and
7.1% (n¼12) were Italians, South Americans and Romanians, re-
spectively. HETs, men who have sex with men (MSM) and IDUs
accounted for 63.4% (n¼83), 31.3% (n¼41) and 5.3% (n¼7)
of the patients. Three out of four subjects were males (n¼129,
76.3%).
The median HIV-1 viral load was 4.71 log copies/mL
(IQR¼3.85–5.30 log copies/mL) and the median CD4 count
was 347 cells/mm3 (IQR¼127–555 cells/mm3). The median
age was 38 years (IQR¼31–46 years).
Table 1 shows the distribution of demographic characteristics
and viro-immunological parameters in Italian, South American
and Romanian naive patients. HETs were prevalent among Ita-
lians and Romanians, while MSM were predominant in South
Americans. Male gender accounted for the majority of Italians
and South Americans. The median age was 40, 33 and
25 years in Italians, South Americans and Romanians, respect-
ively. Thus, risk factor, gender and age were differently distribu-
ted according to the country of origin (P,0.001 for all
comparisons).
Overall, drug resistance was documented in 25.3% (56/221)
of our study population. The prevalence of any resistance was
15.4% [26/169; 11.8% (n¼20) for nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs), 6.5% (n¼11) for non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and 7.1%
(n¼12) for protease inhibitors (PIs)] in naive individuals.
The frequency of TDR was higher in South Americans (23.5%)
compared with Italian and Romanian naive patients (15% and
8.3%, respectively), even though no statistical difference was
detected.
TDR appeared equally distributed among MSM, HETs and IDUs
(19.5%, 14.5% and 14.3%, respectively) and between males and
females (15.5% versus 15.4%, respectively). Table 1 shows the
proportions of TDR class resistance according to the origin of
the patients.
We then evaluated the trends of any and class-specific TDR
over three time intervals (1998–2001, 2002–05 and 2006–
09). A decline of both any and NRTI-associated TDR was
observed over time: from 21.4%, to 23.9% and then to 7.1%
(P¼0.010), and from 14.3%, to 21.1% and then to 3.6%
(P¼0.007), respectively. There was a low prevalence of both
NNRTI- and PI-associated mutations in our dataset, ranging
from 0% to 11.3% and then to 3.6% and from 7.1% to 12.7%
and then to 2.4%, respectively. No significant trend could be
seen in the TDR for these classes of antiretrovirals.
Discussion
Studies of the last decade showed a limited prevalence of TDR
among individuals carrying a non-B clade with a range of
3.2%–11% in Europe, depending on the area and time of
survey.5 – 9 These data may be related to a low exposure to treat-
ment of individuals harbouring non-B subtypes, since they
migrated in recent years from countries where antiretroviral
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drugs were not widely available for the treatment of HIV infec-
tion. Therefore, a continuous monitoring of TDR prevalence
among non-B subtypes is needed to understand the interactions
between ethnic groups that may influence the rate and trend of
TDR, and thus impact the response to treatment.1
Previous TDR evaluations have considered non-B clades
grouped together.4 – 7 However, differences in TDR distribution
may be detected among different subtypes as possible conse-
quences of their specific spread in various populations of differ-
ent countries. A large survey conducted in Italy detected a
significantly higher rate of TDR in subtype B-infected versus
non-B-infected subjects.7 However, our study shows a remark-
able frequency (15.4%) of TDR in the subtype F1-infected popu-
lation. This figure is comparable to the TDR rate in subtype
B-infected patients in Italy.6,7
The high prevalence of TDR (23%) detected in South American
subjects is linked to the homosexual route of infection (82%),
which is predominant in these individuals and, consequently, to
the male gender (94%). On the other hand, TDR was less preva-
lent (8%) among the Romanian population living in our country,
in which the HET route of infection is predominant, with the pro-
portion of females being much higher. These results are in agree-
ment with the epidemiology of HIV infection among people
coming from Romania, where the F1 subtype initially spread
through infected blood products and unsterilized needles.10
Interestingly, TDR was considerably high (15%) also in the
Italian subtype F1-infected population, deserving careful moni-
toring. Among these subjects, the sexual route of transmission
was predominant together with the male gender. Through a
phylogenetic analysis, we recently reported that the majority of
transmission events of the F1 subtype among Italians involved
South American MSM.13 Therefore, the spread of this subtype
in the Italian population may be related to sexual intercourse,
likely through homosexual contacts or transgender prostitution.
Indeed, we found a comparable frequency of TDR both in Italians
and South Americans as a possible consequence of the linkage of
these groups of patients.
Also worthy of note, a declining trend of transmitted resist-
ance to any drug class and NRTIs was highlighted in our study.
These data are consistent with other observations that indicated
that new potent combinations of antiretrovirals may positively
impact on TDR.2 No significant trends of NNRTI- and
PI-associated TDR could be detected in our population, probably
due to the observed biphasic pattern and/or the limited propor-
tions of mutations for drugs of these classes.
We report here that primary resistance in patients with the F1
subtype may largely exceed that of non-B clades in Italy.7 Since
a relevant prevalence of TDR was not previously found in a popu-
lation infected with non-B subtype, this issue deserves further in-
vestigation. The contact tracing of resistant isolates in
epidemiological clusters may clarify the impact of F1 spread on
TDR and help in targeting public interventions to limit the
spread of primary resistance to antiretrovirals.
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Table 1. Demographic characteristics and viro-immunological parameters among Italian, South American and
Romanian drug-naive patients harbouring subtype F1 HIV-1
Patient geographical origina
PItaly (n¼127) South America (n¼17) Romania (n¼12)
Risk factor, % (n) ,0.001
HETs 51.9 (66) 5.9 (1) 66.6 (8)
MSM 19.7 (25) 82.4 (14) 0.0 (0)
IDUs 5.5 (7) 0.0 (0) 0.0 (0)
otherb or unknown 22.8 (29) 11.8 (2) 33.3 (4)
Male, % (n) 82.6 (105) 94.1 (16) 25.0 (3) ,0.001
Age (years), median (IQR) 40 (34–47) 33 (28–40) 25 (19–33) ,0.001
HIV-RNA (log copies/mL), median (IQR) 4.67 (3.72–5.27) 4.09 (3.63–4.70) 4.98 (4.75–5.57) 0.168
CD4 (cells/mm3), median (IQR) 357 (182–565) 384 (118–573) 153 (80–323) NS
Overall TDR, % (n) 15.0 (19) 23.5 (4) 8.3 (1) NS
NRTI resistance 11.8 (15) 17.6 (3) — NS
NNRTI resistance 7.1 (9) 5.9 (1) 8.3 (1) NS
PI resistance 7.9 (10) 5.9 (1) — NS
NS, not significant.
aThirteen individuals carrying F1 subtypes had other or unknown origin.
bOther: professional risk, transfusions and vertical transmission.
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